NOAC (rivaroxaban) vs vitamin K antagonist (VKA)
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) showed no clear difference in all‐cause mortalitya compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyRR 1.45 [0.44, 4.78]3 studies · 425 participantsModerate